Dyne Therapeutics (DYN) Stock Forecast, Price Target & Predictions
DYN Stock Forecast
Dyne Therapeutics stock forecast is as follows: an average price target of $43.88 (represents a 28.83% upside from DYN’s last price of $34.06) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
DYN Price Target
The average price target for Dyne Therapeutics (DYN) is $43.88 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $18.00. This represents a potential 28.83% upside from DYN's last price of $34.06.
DYN Analyst Ratings
According to 8 Wall Street analysts, Dyne Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DYN stock is 1 'Strong Buy' (12.50%), 7 'Buy' (87.50%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dyne Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Michael Ulz | Morgan Stanley | $52.00 | $43.64 | 19.16% | 52.67% |
| Aug 13, 2024 | Edward Tenthoff | Piper Sandler | $53.00 | $43.07 | 23.06% | 55.61% |
| Jun 24, 2024 | Eun Yang | Jefferies | $42.00 | $35.94 | 16.86% | 23.31% |
| Jun 17, 2024 | Francois Brisebois | Oppenheimer | $55.00 | $32.15 | 71.07% | 61.48% |
| May 21, 2024 | Keay Nakae | Chardan Capital | $42.00 | $35.38 | 18.71% | 23.31% |
| May 20, 2024 | Andrew Fein | H.C. Wainwright | $48.00 | $33.83 | 41.91% | 40.93% |
| May 20, 2024 | Paul Matteis | Stifel Nicolaus | $41.00 | $27.68 | 48.12% | 20.38% |
| Apr 30, 2024 | Michael Ulz | Morgan Stanley | $40.00 | $25.46 | 57.11% | 17.44% |
| Nov 29, 2022 | - | J.P. Morgan | $18.00 | $10.46 | 72.08% | -47.15% |
| Sep 06, 2022 | Edward Tenthoff | Piper Sandler | $23.00 | $11.60 | 98.28% | -32.47% |
The latest Dyne Therapeutics stock forecast, released on Aug 14, 2024 by Michael Ulz from Morgan Stanley, set a price target of $52.00, which represents a 19.16% increase from the stock price at the time of the forecast ($43.64), and a 52.67% increase from DYN last price ($34.06).
Dyne Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 8 |
| Avg Price Target | - | $50.50 | $46.63 |
| Last Closing Price | $34.06 | $34.06 | $34.06 |
| Upside/Downside | -100.00% | 48.27% | 36.91% |
In the current month, the average price target of Dyne Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dyne Therapeutics's last price of $34.06. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 14, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Jefferies | Buy | Buy | Hold |
| Jun 17, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 20, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 20, 2024 | Jefferies | Buy | Buy | Hold |
| May 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 20, 2024 | Guggenheim | Buy | Buy | Hold |
Dyne Therapeutics's last stock rating was published by Oppenheimer on Sep 03, 2024. The company gave DYN a "Outperform" rating, the same as its previous rate.
Dyne Therapeutics Financial Forecast
Dyne Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $1.67M |
| High Forecast | - | - | - | - | - | - | - | $1.67M |
| Low Forecast | - | - | - | - | - | - | - | $1.67M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Surprise % | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DYN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Dyne Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict DYN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Dyne Therapeutics's previous annual EBITDA (undefined) of $NaN.
Dyne Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-78.82M | $-74.75M | $-70.86M | $-67.35M | $-68.11M | $-65.17M | $-66.39M | $-74.01M |
| High Forecast | $-78.82M | $-74.75M | $-70.86M | $-67.35M | $-68.11M | $-55.08M | $-66.39M | $-74.01M |
| Low Forecast | $-78.82M | $-74.75M | $-70.86M | $-67.35M | $-68.11M | $-73.44M | $-66.39M | $-74.01M |
| Surprise % | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DYN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Dyne Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DYN last annual SG&A of $NaN (undefined).
Dyne Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.85 | $-0.81 | $-0.77 | $-0.73 | $-0.74 | $-0.70 | $-0.72 | $-0.80 |
| High Forecast | $-0.85 | $-0.81 | $-0.77 | $-0.73 | $-0.74 | $-0.60 | $-0.72 | $-0.80 |
| Low Forecast | $-0.85 | $-0.81 | $-0.77 | $-0.73 | $-0.74 | $-0.79 | $-0.72 | $-0.80 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Dyne Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DYN previous annual EPS of $NaN (undefined).
Dyne Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| DYN | Dyne Therapeutics | $34.06 | $43.88 | 28.83% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
DYN Forecast FAQ
Is Dyne Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, Dyne Therapeutics (DYN) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of DYN's total ratings.
What is DYN's price target?
Dyne Therapeutics (DYN) average price target is $43.88 with a range of $18 to $55, implying a 28.83% from its last price of $34.06. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Dyne Therapeutics stock go up soon?
According to Wall Street analysts' prediction for DYN stock, the company can go up by 28.83% (from the last price of $34.06 to the average price target of $43.88), up by 61.48% based on the highest stock price target, and down by -47.15% based on the lowest stock price target.
Can Dyne Therapeutics stock reach $50?
DYN's highest twelve months analyst stock price target of $55 supports the claim that Dyne Therapeutics can reach $50 in the near future.
What are Dyne Therapeutics's analysts' financial forecasts?
Dyne Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.67M (high $1.67M, low $1.67M), average EBITDA is $0 (high $0, low $0), average net income is $-274M (high $-264M, low $-282M), average SG&A $0 (high $0, low $0), and average EPS is $-2.958 (high $-2.849, low $-3.048). DYN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-292M (high $-292M, low $-292M), average SG&A $0 (high $0, low $0), and average EPS is $-3.154 (high $-3.154, low $-3.154).